1. Home
  2. IRD vs CENN Comparison

IRD vs CENN Comparison

Compare IRD & CENN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • IRD
  • CENN
  • Stock Information
  • Founded
  • IRD 2018
  • CENN 2013
  • Country
  • IRD United States
  • CENN United States
  • Employees
  • IRD N/A
  • CENN N/A
  • Industry
  • IRD
  • CENN Auto Manufacturing
  • Sector
  • IRD
  • CENN Consumer Discretionary
  • Exchange
  • IRD NYSE
  • CENN Nasdaq
  • Market Cap
  • IRD 36.1M
  • CENN 32.4M
  • IPO Year
  • IRD N/A
  • CENN N/A
  • Fundamental
  • Price
  • IRD $1.15
  • CENN $1.02
  • Analyst Decision
  • IRD Strong Buy
  • CENN
  • Analyst Count
  • IRD 1
  • CENN 0
  • Target Price
  • IRD $8.00
  • CENN N/A
  • AVG Volume (30 Days)
  • IRD 154.1K
  • CENN 120.8K
  • Earning Date
  • IRD 02-19-2025
  • CENN 02-18-2025
  • Dividend Yield
  • IRD N/A
  • CENN N/A
  • EPS Growth
  • IRD N/A
  • CENN N/A
  • EPS
  • IRD N/A
  • CENN N/A
  • Revenue
  • IRD $8,381,000.00
  • CENN $37,052,841.00
  • Revenue This Year
  • IRD N/A
  • CENN N/A
  • Revenue Next Year
  • IRD $29.37
  • CENN N/A
  • P/E Ratio
  • IRD N/A
  • CENN N/A
  • Revenue Growth
  • IRD N/A
  • CENN 142.48
  • 52 Week Low
  • IRD $0.81
  • CENN $0.97
  • 52 Week High
  • IRD $2.77
  • CENN $2.30
  • Technical
  • Relative Strength Index (RSI)
  • IRD N/A
  • CENN 33.14
  • Support Level
  • IRD N/A
  • CENN $0.97
  • Resistance Level
  • IRD N/A
  • CENN $1.15
  • Average True Range (ATR)
  • IRD 0.00
  • CENN 0.06
  • MACD
  • IRD 0.00
  • CENN -0.01
  • Stochastic Oscillator
  • IRD 0.00
  • CENN 22.22

About IRD OPUS GENETICS INC

Opus Genetics Inc is a clinical-stage ophthalmic biopharmaceutical company developing therapies to treat patients with inherited retinal diseases (IRDs) and therapies to treat patients with other retinal and refractive disorders. The pipeline includes adeno-associated virus (AAV)-based gene therapies that address mutations in genes that cause different forms of bestrophinopathy, Leber congenital amaurosis (LCA) and retinitis pigmentosa. The pipeline also includes Phentolamine Ophthalmic Solution 0.75%, a non-selective alpha-1 and alpha-2 adrenergic antagonist to reduce pupil size, and APX3330, a novel small-molecule inhibitor of Ref-1 to slow the progression of non-proliferative diabetic retinopathy.

About CENN Cenntro Electric Group Limited

Cenntro Inc is a designer, manufacturer, distributor, and service provider of commercial vehicles. Its vehicles include Metro, Logistar 400, Logistar 200, Neibor 200, and ORV. The company's geographical segments include Europe, America, and Asia.

Share on Social Networks: